The responsiveness ofisolated guinea pig lung parenchymal strips to substance P was enhanced by at least 100-fold in the presence of the endopeptidase inhibitors phosphoramidon (1 gM) or thiorphan (1 &M), but not with the converting enzyme inhibitor, captopril, or an inhibitor of serum carboxypeptidase N (both 1 t&M). Responses of guinea pig tracheal rings to substance P were also markedly potentiated by phosphoramidon. The increase in tissue responsiveness by these inhibitors was relatively specific for substance P among several other spasmogenic peptides, including formyl-methionyl-leucyl-phenylalanine and the complement peptides C3a and C5a. The enhanced responses appear to result from a decrease in the rate of substance P degradation in the presence of neutral endopeptidase inhibitors. Specific binding of substance P to its receptor on bronchial membranes was increased by three to fourfold in tIhe presence of phqsphoramidon.
Introduction
Substance P is a naturally occurring 1 1-residue peptide which has been shown to participate in neurogenic bronchoconstriction (1) (2) (3) (4) (5) . The peptide has been identified by immunohistochemical techniques in neural fibers of guinea pig trachea and bronchus, and is depleted upon vagal stimulation or prolonged treatment with capsaicin (5), the pungent agent of hot peppers. Intravenous administration of substance P in guinea pigs causes acute bronchospasm, hypotension, and increases in vascular permeability (4) . In vitro, substance P has also been shown to contract isolated guinea pig tracheal and lung parenchymal tissues in a muscle bath apparatus (6) (7) (8) . Pharmacologic studies have shown that the contractile effects ofthe peptide are independent ofhistamine, catecholamines, and serotonin (5, 6, 8) . Variable results have been reported with cyclooxygenase inhibitors, one group observing enhanced responses in the presence ofindomethacin (8) , and another group finding no change with meclofenamate (6) .
substance P-induced spasmogenic activity in vitro, it is thought that the peptide may act directly on smooth muscle (5, 9) .
A recent report demonstrated that substance P is a substrate for human kidney neutral endopeptidase (EC 3.4.24.11) (10), an enzyme originally characterized for its ability to degrade enkephalins (1 1) . This enzyme has substrate specificity similar to that ofthermolysin (12, 13) . It is thought to be an integral membrane protein and has been localized immunohistochemically to lung and kidney epithelium, neutrophil membranes, and brain (14) (15) (16) . Like thermolysin, it is inhibited by the substrate analogues, phosphoramidon and thiorphan (17) (18) (19) (20) . Its presence in brain and ability to degrade enkephalins and substance P have been interpreted as indicating a primary function ofthe enzyme in catabolizing these neuropeptides (16, 21, 22) .
In the case of other spasmogenically active peptides, bradykinin and the complement anaphylatoxins, C3a, C4a, and C5a, protease or exopeptidase activity has been demonstrated to provide an effective control mechanism (23, 24) . We reasoned that the relatively weak spasmogenic activity of substance P on guinea pig lung parenchymal strips could be due to its rapid degradation. To test this hypothesis, we examined the effect of inhibiting proteolytic activity on substance P responses in this tissue. Our findings demonstrate marked potentiation of contractile activity in the presence of neutral endopeptidase inhibitors.
Methods
Reagents and buffers. Substance P, D-Pro2, D-Trp7, D-Phe'-substance P, formyl-methionyl-leucyl-phenylalanine (fMLP),' phosphoramidon, chymostatin, leupeptin, bacitracin, and acetylcholine (ACh) were all obtained from Sigma Chemical Co, St. Louis, MO. "II-Substance P (labeled with Bolton and Hunter reagent) was purchased from Amersham Corp., Arlington Heights, IL. Captopril (SQ 14,225) was a generous gift of The Squibb Institute for Medical Research, Princeton, NJ. DL-2-mercaptomethyl-3-guanidinoethylthiopropanoic acid (MGPA) was purchased from Calbiochem-Behring Corp., San DieFo, CA, and thiorphan was purchased from Peninsula Laboratories, Belmont, CA. Human C5a was obtained as a recombinant peptide from Escherichia coli lysates, reconstituted and purified as previously described (25) . C3a was purified from complement-activated porcine serum as described (26) . The buffer used throughout was a modified Tyrode's solution which contained 137 mM NaC1, 2.7 mM KC1, 1.8 mM CaC12, I mM MgCl2, 0.36 mM NaH2PO4, 12 mM NaHCO3, and 5.5 mM dextrose, pH 7.4 (27) .
Preparation of lung strips. Male Hartley guinea pigs of 300-500 g (Charles River Breeding Laboratories) were the source of all tissue preparations. Lung parenchymal strips were prepared from lungs perfused with Tyrode's buffer using a modification of the method previously described (28). 20 Recovery ofsubstance Pfrom lung strips. Lung parenchymal tissues were prepared as described above for muscle bath experiments and placed in Tyrqde's buffer at 160 mg wet weight tissue in 5 ml buffer, at 370C in the presence of 1 AM phosphorami~don; 1 MM captropril, 1 AM MGPA, or vehicle alone. Tissues were preincubated with the inhibitor for 5 min, substance P was added to a final concentration of 1 MM, and incubation was continued an additional 5 min. Degradation was terminated by transferring each supernatant solution to a second tube containing acetic acid to make I M and lyophylized. Samples were redissolved in 0.5-and 0. l-ml aliquots (equivalent to I nmol undigested peptide) injected on an Anspec Cl reverse-phase high performance liquid chromatography (HPLC) column. Substance P was resolved with a two-step linear gradient from 6 to 18% acetonitrile in 0.1% trifluoroacetic acid (TFA) over 5 min, followed by a gradient from 18 to 48% acetonitrile in 0.1% TFA over 20 min. The column was eluted at I ml/min and monitored at 220 nm.
Under these conditions substance P elutes at 14.5-15 min. The amount of intact peptide remaining was determined from the peak height relative to peak heights established for known standards.
Rate ofsubstance P degradation. Guinea pig lung membranes were prepared essentially according to procedures described previously (30) . Lungs from three guinea pigs were perfused with Tyrode's buffer and homogenized by polytron (Brinkmann Instruments Inc.? Westbury, NY) in 1O vol of ice-cold 50 mM Tris-HCl, pH 7.0, for three 1O-s periods at setting 6. The homogenates were centrifuged at 1,000 g for 1O min. The supernatants were then centrifuged at 40,000 g for 15 min. Pellets obtained were resuspended in 50 mM Tris-HCI, pH 7.0, and washed three times by centrifuging for 15 min at 40,000 g. Pelleted material was finally resuspended in the same buffer at 0.5 mg protein/ml and incubated with 100 AM substance P, and 1 MM phosphoramidon, 1 AM MGPA, or vehicle alone at 370C, removing duplicate 100l-Ml aliquots at various times up to 20 min. Degradation was stopped by heating the mixtures to 1 100C for 5 min-followed by centrifugation at 7,000 g for 2 min. The amount of intact substance P remaining was quantitated by reversephase HPLC as described above and the rate of degradation was determined by regression analysis of the substance P remaining as a function of time.
Effect ofphosphoramidon on substance P binding to bronchial membranes. Guinea pig lungs (n = 3) were mechanically stripped ofas much alveolar tissue as possible. The remaining bronchial tissues were homogenized in 10 vol of 10 mM Tris-HCI, pH 7.4, containing 0.25 M sucrose, 100 Mg/ml bacitracin, and 0.1 mM PMSF, for six 10-s periods on ice. The homogenate was centrifuged at 1,000 g for 10 mim. The supernatant was centrifuged at 30,000 g for 30 min, then pelleted material was resuspended in 50 mM Tris-HCl, pH 7.4, containing 3 mM MnCl2, and centrifuged again at 30,000 g for 30 min. Pellets were stored at -80'C until used.
For substance P binding experiments, membranes were resuspended at 0.5 mg/ml in 50 mM Tris-HCI, pH 7.4, containing 3 mM MnCI2, 1% bovine saline albumin, 4 Mg/ml leupeptin, 4 Mg/ml chymostatin, and 40
Mg/ml bacitracin, with or without 10M M phosphoramidon. 25I-ubstance P (50-70 cpm/fmol) was added at 5 nM and incubated at 250C. Triplicate I00-Ml samples were removed as a function oftime and filtered (Whatman GF/A filters soaked in 0.1% polyethyleneimine for 24 hr at 4VC), and washing rapidly three times with 3.5 ml of ice-cold 50 mM Tris-HCl, pH 7.4, containing 3 mM MnCl2. Radioactivity on the filters was determined by scintillation counting. Specific binding was defined as the difference in counts bound in the absence and presence of 5 MM unlabeled substance P.
Protein determination. Protein concentrations were determined by the method of Bradford (31) .
Statistical analysis. Analysis of variance for substance P responses in tissues from different guinea pigs indicates, at P < 0.05, that intraanimal variation is no greater than intratissue variation. All values are expressed as mean±SE. Comparisons of corresponding data points from control and experimental tissues were made using unpaired two-tailed t test. Mean values were considered significantly different for P < 0.05.
Results
Potentiation ofsubstance P responses by neutral endopeptidase inhibitors. The concentration-response curve for substance Pinduced contractions of guinea pig lung parenchymal strips relative to ACh is shown in Fig. 1 . Under the conditions used, substance P is a relatively weak agonist for inducing contractions of these tissues, stimulating maximal responses equivalent to only 30% of the ACh maximum. When tissues were pretreated with phosphoramidon (1 gM), a competitive inhibitor of neutral endopeptidase, peptide responses were markedly potentiated, shifting the concentration-response curve -100-fold to the left and increasing the magnitude of maximal responses to 100% of the ACh response ( Fig. 1) (P < 0.001 vs. control at concentrations 2 I0-7M). Phosphoramidon had no effect on responses to ACh, 2 j~g/ml resulting in a contraction of 108±5% (n -16) of the control response without drug.
Another competitive inhibitor of neutral endopeptidase, thiorphan (1 MM), showed similar potentiation of substance P responses ( Fig. 1) (P < 0.001 vs. control at concentrations 2 10-7 M). The effect appeared tobe specific for neutral endopeptidaselike activity in lung parenchymal tissues since similar potentiation was not observed with relatively specific inhibitors of other proteases. MGPA (1 WM), a carboxypeptidase N inhibitor, had no significant effect on substance P-stimulated contractions of parenchymal tissues (P > 0.05). Captopril (1 MM) caused a less marked potentiation than phosphoramidon or thiorphan, shifting the concentration-response curve to the left by a small amount and increasing maximal contractions to 40% ofthe ACh maximum (Fig. 1) . The difference in responses was significant (P < 0.05) only at l0-5 M substance P.
Additional paired experiments were performed to rule out the possibility of a random result in the above unpaired experiments. The responses oftissues from a single animal in Tyrode's buffer alone, or in the presence ofphosphoramidon or captopril (both at 1 ,tM) to substahce P were compared. The 50% effective concentration (EC50) for substance P (17±4% of ACh) occurred at 10-6 M peptide in the absence of any inhibitors or with captopril (n -4 for each). In the presence of 1 ,uM phosphoramidon, this response was achieved at 5 X 10-8 M substance P (n = 4). At 5 X 10-6 M substance P, the magnitude of the response in control tissues was only 33% of that observed in the presence of phosphoramidon (33±4 vs. 100±10% of ACh, n = 4 for each). The responses obtained in paired experiments were not significantly different from unpaired data (P < 0.05).
Recovery ofsubstance Pfrom lung parenchymal strips. Previous investigators have shown that phosphoramidon and thiorphan inhibit the proteolytic activity of neutral endopeptidase (17, 19) . The pharmacologic data of Fig. 1 are consistent with such action, i.e., potentiation of the biological activity of substance P as a result of inhibiting its degradation. To examine this possibility, the amount of intact substance P remaining after 5 min incubation with lung parenchymal tissues was determined. The amount of tissue per milliliter of buffer was similar to that used in muscle baths and the incubation period chosen was comparable to the time required to develop a tissue response. Substance P was added at an initial concentration of 1 gM.
HPLC profiles of the substance P recovered from these incubation mixtures are shown in Fig. 2 . Recovery of the peptide from control mixtures without tissue was essentially quantitative (2 97%) . Under these incubation conditions, only 9.5% of the substance P added was recovered intact after 5 min. Inclusion of 1 juM phosphoramidon provided significant protection from degradation, with 47% of the peptide recovered as intact substance P after 5 min (P < 0.005). Neither captopril nor MGPA had a significant effect compared with the control (P = 0.05) (Fig. 2, Table I ).
In preparation for the receptor binding experiments described below, the degradation of substance P was additionally studied using guinea pig lung membrane preparations (Table II Fig.   3 . This formylated tripeptide is much more potent than substance P for contracting lung parenchymal strips, with threshold responses at subnanomolar concentrations and maximal contractions in excess of 200% of ACh. Inhibition of neutral endopeptidase activity with phosphoramidon resulted in only a three-to fourfold increase in fMLP responses, a much smaller potentiation than was observed for substance P. Contractile responses are significantly different from control (P < 0.05) only for fMLP concentrations of 5 X 10-9 M and below.
The spasmogenic activity ofthe complement anaphylatoxin peptides, C3a and COa, was also tested for potentiation by phosphoramidon (Fig. 3) . CSa is active in a concentration range similar to fMLP and C3a causes responses in a range comparable to substance P in the absence of protease inhibitors. Phosphoramidon did not significantly effect the concentration-response curve for either of these peptides (P = 0.50) (Fig. 3) . Inhibition ofthepotentiated substance P response by a specific receptor antagonist. The snythetic peptide antagonist ofsubstance Pi D-Pro2, D-Phe7, -Trpo-substance P has been shown to block substance P responses by binding nonproductively to the substance P receptor (34) . In the presence of phosphoramidon, the substance P concentration-response curve was significantly inhibited (P < 0.05 for all concentrations except I0-' M) by 1 AM D-Pro2, D-Phe7, D-Trp9-substance P (Fig. 4) , supporting the evidence for an increase in activity of substance P on its receptor on lung parenchymal strips in the presence ofphosphoramidon. At higher concentrations the peptide antagonist also expresses weak agonist activity (not shown).
Effect ofphosphoramidon on specific binding ofsubstance P 10-6 Substance P Conc., M Figure 4 . Concentration-response curves for substance P in the presence of 1 IAM phosphoramidon alone, as in Fig. 1 (o) or in addition to 1 MM D-Pro2, D-Phe7, D-Trp9-substance P (o). All points are the mean±SE (n = 4-6). Conc., Concentration; max, maximum.
substance P in other tissues (34) (35) (36) . In the absence ofthe neutral endopeptidase inhibitor in combination with these other compounds, specific uptake of substance P at 250C reached a maximum of 80-100 fmol/mg protein by 2-5 min and rapidly dropped to nearly undetectable levels (Fig. 5) . When 10 OM phosphoramidon was combined with the other protease inhibitors, uptake reached a maximum by 10 min and remained stable for at least 10 min thereafter at a level almost four times as great as in incubation mixtures without phosphoramidon (Fig. 5) . The concentration of 10 MAM phosphoramidon was chosen to ensure the stability of the relatively low '25I-substance P levels in these incubation conditions. This agent is not reported to have nonspecific effects at this concentration.
Effect of neutral endopeptidase inhibitors on substance Pinduced responses ofguinea pig tracheal tissues. The potency of substance P for contracting guinea pig tracheal rings in Tyrode's buffer alone is considerably greater than for contracting lung parenchymal strips (Fig. 6, and reference 8 ). Threshold contractions of trachea were observed at 10-100 nM substance P and maximal responses induced were equivalent to 120% of the ACh maximum response (Fig. 6 ). In the presence of phosphoramidon, tracheal responses are potentiated -50-fold and maximal responses are increased to 180% of the ACh maximum (P < 0.01 for all concentrations. As observed for lung parenchymal strips, captopril produced a trend towards increasing responses to substance P but did not significantly shift the dose-response curve (P = 0.05).
Discussion
The work reported here was prompted by the observation that substance P is a relatively weak agonist for producing contractile responses in guinea pig lung parenchymal strips under the experimental conditions normally used (i.e., Tyrode's buffer with no additives) (26, 29) . Reports that substance P is a substrate for neutral endopeptidase (10, 37) , coupled with observations that this enzyme is present in lung epithelium (15, 38) , encouraged us to examine the contractile activity of the peptide in the presence of inhibitors ofthis enzyme. Our findings show potentiation ofsubstance P responses by 100-fold on lung parenchymal strips in the presence of relatively specific inhibitors of neutral endopeptidase, including phosphoramidon and thiorphan (Fig.  1) . Responses of tracheal tissues were also greatly enhanced in the presence of phosphoramidon, shifting the concentration-response curve to 50-fold lower concentrations (Fig. 6) .
Angiotensin converting enzyme is also reported to degrade substance P (10); however, captopril, at 1 MiM, potentiates the substance P concentration-response curve for lung parenchymal strips by a relatively small amount, statistically significant only at the highest substance P concentration tested (Fig. 1) . Tracheal tissue responses were not significantly affected (Fig. 6 ). Higher concentrations of these inhibitors were not tested in this system since previous investigations have shown, using purified enzymes, that 1 MM captopril completely blocks substance P degradation by angiotensin converting enzyme and similarly, 1 gM phosphoramidon completely blocks degradation of this peptide by purified neutral endopeptidase (10) . Thus, in lung tissues, the data presented here indicate that neutral endopeptidase, or a neutral endopeptidase-like enzyme, is highly active in limiting the biological activity of substance P, and is more important in this regard than angiotensin converting enzyme.
Incubation of 1 MAM substance P with guinea pig lung tissues for 5 min at 370C resulted in degradation of 90% of the peptide (Fig. 2, e-J 10---protection from degradation, with 47% ofthe peptide remaining intact after 5 min. Neither captopril nor MGPA improved the recovery of substance P from lung strips compared with the control.
The rate of substance P degradation was also studied using washed guinea pig lung membrane preparations, which are predicted to be a source of neutral endopeptidase activity (15) . In incubation mixtures containing 500 ug membrane protein/ml and 100 ,M substance P, peptide was degraded at a rate of 8.1 nmol/min per mg protein (Table II) . In the presence of phosphoramidon, this rate was inhibited by 65% to 2.9 nmol/min per mg protein. The serum carboxypeptidase inhibitor, MGPA, had no effect compared with the control. Thus the phosphoramidon-induced potentiation of substance P responses appears to result from a decreased rate of degradation of the peptide.
Clearly, substance P is still degraded by other enzymes present in lung tissues, even in the presence of phosphoramidon (Table  I) . Investigations of binding sites for this peptide in rat brain and guinea pig gastrointestinal smooth muscle preparations have demonstrated a requirement for a combination of leupeptin, chymostatin, and bacitracin to prevent degradation (35, 36, 39) . This combination of inhibitors did not block substance P degradation by crude lung membrane preparations. However, when phosphoramidon was also added, recovery of intact substance P was 70-80% after 30 min incubation at 250C (data not shown). When tested on guinea pig lung parenchymal strips in the muscle bath, this combination of inhibitors did not potentiate substance P responses more than phosphoramidon alone (data not shown), which suggested that this additional proteolytic activity is not kinetically competitive with the initial interaction of substance P with its cellular receptor.
To confirm the competitive nature of phosphoramidon-inhibitable substance P degradation with binding of the peptide to its receptor, uptake of the peptide was studied as a function oftime. Experiments were initially performed using a membrane preparation from the entire lung; however, the data obtained indicate, as previously reported (9) , that this preparation does not contain a sufficiently high receptor density to detect specific binding. Autoradiographic localization of substance P receptors in guinea pig lung indicate the highest receptor density on bronchial smooth muscle (9) , and therefore the bronchial membrane preparation described was used instead. This preparation is estimated to be enriched three-to fourfold in bronchial membranes compared with the intact lung. Phosphoramidon resulted in a 3.5-to 4-fold increase in the specific binding of '25I-substance P compared with the control without neutral endopeptidase inhibitor (Fig. 5) . Binding increased and remained stable for at least 20 min with phosphoramidon, but returned to nearly undetectable levels within 10 min in the controls.
The selectivity of the phosphoramidon-induced hyperresponsiveness was relatively specific for substance P among the additional peptide spasmogens tested. The formylated tripeptide, fMLP, was potentiated only three-to fourfold by phosphoramidon (Fig. 3) . Connelly et al. (14) report degradation of fMLP by neutral endopeptidase present on human neutrophil membranes. However, this enzyme activity in lung appears to be a relatively unimportant control mechanism for fMLP-induced contractile responses ofisolated lung tissues compared with substance P.
The spasmogenic activities of the anaphylatoxin peptides, C3a and C5a, were not significantly affected by neutral endopeptidase inhibitors (Fig. 3 ). Both these peptides are known to be inactivated by serum carboxypeptidase (23) . C3a has additionally been shown to be a substrate for purified angiotensin converting enzyme in vitro (40) , and evidence exists for inactivation of C5a by aminopeptidase or endopeptidase activity (41, 42) . These spasmogenic peptides may be too large to be effective substrates for neutral endopeptidase.
The pharmacologic and receptor-binding data indicate that the increase in longevity of substance P in lung tissues is manifested by an increase in the interactions between the peptide and its receptor. This is further supported by inhibition of phosphoramidon-potentiated substance P responses in the presence of the specific receptor antagonist, D-Pro2, D-Phe7, DTrp9-substance P. This peptide analogue, at 1 MAM, shifted the substance P dose-response curve, in the presence of phosphoramidon, to five-to tenfold higher concentrations (Fig. 4) .
These data identify the potential activity of substance P for contracting guinea pig lung parenchymal strips and tracheal rings in vitro when degradation by neutral endopeptidase-like activity is blocked. Thus, this peptide is a much more potent agonist for producing smooth muscle contraction in these tissues than was previously appreciated. Furthermore, these findings suggest that the levels of neutral endopeptidase activity in the lung play a key role in controlling the biological activity ofendogenous substance P.
Little information is available relative to the control of expression of this enzyme activity in vivo. Johnson et al. (43) reported significant elevation in neutral endopeptidase activity in the blood ofpatients with adult respiratory distress syndrome. These authors speculated that this activity may derive from injured cells in the lung (14) . If this circumstance results in diminished levels of enzyme activity in the lung, then, based on the present report, one might expect to observe marked potentiation of the pathophysiologic effects of endogenously released substance P. This report may therefore expose a potentially important and heretofore unrecognized control mechanism ofpulmonary responses mediated by substance P under the direct control of neutral endopeptidase.
